Bio-Rad Laboratories, Inc. (NYSE:BIO) Holdings Reduced by Amundi

Amundi lowered its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 45.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 20,042 shares of the medical research company’s stock after selling 16,596 shares during the quarter. Amundi owned about 0.07% of Bio-Rad Laboratories worth $6,902,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the business. Venturi Wealth Management LLC increased its position in Bio-Rad Laboratories by 2,175.0% in the 4th quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 87 shares during the period. Gladius Capital Management LP bought a new position in shares of Bio-Rad Laboratories in the third quarter worth $32,000. Asset Planning Inc acquired a new position in shares of Bio-Rad Laboratories during the fourth quarter valued at $33,000. UMB Bank n.a. raised its stake in shares of Bio-Rad Laboratories by 41.6% during the fourth quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock valued at $36,000 after purchasing an additional 32 shares in the last quarter. Finally, Cape Investment Advisory Inc. acquired a new stake in Bio-Rad Laboratories in the fourth quarter worth about $38,000. Institutional investors own 65.24% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on BIO. Wells Fargo & Company lowered their target price on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 12th. Royal Bank of Canada reissued an “outperform” rating and set a $481.00 target price on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. Finally, StockNews.com lowered Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, February 17th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, Bio-Rad Laboratories has an average rating of “Moderate Buy” and an average price target of $395.20.

Bio-Rad Laboratories Price Performance

BIO stock opened at $255.34 on Friday. The firm has a 50-day moving average of $311.97 and a two-hundred day moving average of $328.01. The firm has a market capitalization of $7.15 billion, a PE ratio of -3.93 and a beta of 0.99. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories, Inc. has a one year low of $244.00 and a one year high of $387.99.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. On average, analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.